Navigation Links
Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC
Date:5/21/2013

Raleigh, NC (PRWEB) May 21, 2013

Clinverse, Inc., a global technology and financial services company for clinical trials, announced today it has formed a strategic alliance with Aggregate Spend Solutions, LLC. Clinverse’s ClinPay® FLS eClinical commerce platform aggregates data collected through an automated investigator payment process. SpendMD™, Aggregate Spend Solutions’ recently-launched flagship product, is the only complete solution for tracking and reporting transfer of value at investigator meetings or any meeting where healthcare providers (HCPs) receive varying types of compensation from sponsors in exchange for their involvement. Together, the combined solution provides a “one-stop-shop” for the collection of data required by the Sunshine Act, also known as the Physician Payment Sunshine Act (PPSA).

“We are pleased to announce this strategic partnership with SpendMD. Not only are we able to provide our clients with the ability to collect investigator payment data currently generated by ClinPay FLS, but we are now able to automate the acquisition of investigator payment data collected during investigator meetings and other sponsor-related events,” said Steve Ayala, Clinverse President and head of partnerships. “We know that compliance with the Sunshine Act requirements have been, and continue to be, a significant concern for our clients and the industry as a whole. We are investing our resources, time and expertise to develop integrated solutions to address these concerns through the automation of the data collection and reporting process required by CMS.”

ClinPay FLS’ open application programming interface (API) allows for seamless integration with SpendMD, as well as other clinical trial platforms (e.g., EDS, CTMS, and IxRS applications), meeting planning software, or any other electronic systems used to accurately report various direct or indirect payments made to HCPs as required by the new legislation. With the Sunshine Act now requiring the collection of data beginning August 1, 2013, the timing of this partnership benefits clinical trial sponsors looking to gain compliance and provide a comprehensive, automated solution for tracking total investigator spend, both direct and indirect, while alleviating a time-intensive burden from sponsors.

John Lewis, CEO of Aggregate Spend Solutions, stated, “We understand the complexities unique to transfer of value spend capture – working with multiple vendors, meeting-related expenses, and other issues. Our partnership with Clinverse allows us to provide our clients with our expertise and proven technology, while also providing them access to a centralized and scalable aggregate spend solution anchored by Clinverse’s proven investigator payment platform. We look forward to working with Clinverse and continuing to provide our clients with all of the services and technology required to meet the Sunshine Act reporting requirements that are looming.”

About Aggregate Spend Solutions, LLC

Aggregate Spend Solutions, LLC was formed as a result of the new and stringent reporting requirements of the Physicians Payment Sunshine Act. SpendMD™, sunshine tracking and reporting is the organization’s key software product that provides the Health and Life Science Industries with the only complete solution for tracking and reporting “indirect spend” for HCP Meetings. Based in Raleigh, North Carolina with global development centers, Aggregate Spend Solutions is a key leader in the design, development, implementation and support of data aggregation products and services. For more information, please visit http://www.spendmd.com.

About Clinverse, Inc.

Clinverse, Inc. is a global technology and financial services company that delivers highly secure, cloud-based financial management and payment solutions for the clinical trials industry. Founded in 2008 and headquartered in Raleigh, NC, the company delivers clinical financial solutions through the only truly collaborative and transparent financial management and payment platform. Used by leading BioPharma companies, Clinverse has developed ClinPay® FLS, a fully-configurable, game-changing SaaS-based platform which manages tens of millions of dollars in financial transactions for thousands of Global sites while supporting payments in 140 different currencies. For more information, please visit http://www.clinverse.com.

Read the full story at http://www.prweb.com/releases/2013/5/prweb10751165.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
2. VaxyGen Assay Services, LLC Announces Launch of Custom Bioassay Services and Operations
3. Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference
4. ACORN Research, LLC Announces Partnership with AdeptBio, LLC
5. GeoVax Labs, Inc. Announces Nine Month 2011 Financial Results
6. WuXi PharmaTech Announces Third-Quarter 2011 Results
7. Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
8. Spherix Announces Third Quarter Financial Results
9. Modern Mobility Aids, Inc. Announces November 30, 2011 Closing of Lumigene Acquisition
10. MedImmune Announces Winners of Its 6th Annual Global Abstract Competition
11. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, a leader in clinical ... Patient Recruitment and Retention Tips.” Partnering with experienced clinical research professionals, Mosio revisits ... tips, tools, and strategies for clinical researchers. , “The landscape of how patients ...
(Date:6/23/2016)... 2016   Boston Biomedical , an industry ... to target cancer stemness pathways, announced that its ... Drug Designation from the U.S. Food and Drug ... including gastroesophageal junction (GEJ) cancer. Napabucasin is an ... cancer stemness pathways by targeting STAT3, and is ...
(Date:6/23/2016)... June 23, 2016 A person commits a crime, ... scene to track the criminal down. An outbreak ... and Drug Administration (FDA) uses DNA evidence to track down ... Sound far-fetched? It,s not. The FDA has increasingly used ... investigations of foodborne illnesses. Put as simply as possible, whole ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... (Yeast and Mold) microbial test has received AOAC Research Institute approval 061601. , ... tests introduced last year,” stated Bob Salter, Vice President of Regulatory and Industrial ...
Breaking Biology Technology:
(Date:5/3/2016)... 2016  Neurotechnology, a provider of high-precision biometric ... Biometric Identification System (ABIS) , a complete system ... ABIS can process multiple complex biometric transactions with ... fingerprint, face or iris biometrics. It leverages the ... MegaMatcher Accelerator , which have been used ...
(Date:4/19/2016)... -- The new GEZE SecuLogic access control ... system solution for all door components. It can be ... interface with integration authorization management system, and thus fulfills ... dimensions of the access control and the optimum integration ... considerable freedom of design with regard to the doors. ...
(Date:3/31/2016)... 2016   LegacyXChange, ... "Company") LegacyXChange is excited to release its ... to be launched online site for trading 100% guaranteed ... will also provide potential shareholders a sense of the ... an industry that is notorious for fraud. The video ...
Breaking Biology News(10 mins):